Drugmaker Eli Lilly beats estimates, raises 2018 profit forecast

FAN Editor

Jan 31 (Reuters) – Eli Lilly and Co reported a bigger-than-expected quarterly profit on Wednesday, helped by demand for new diabetes and psoriasis treatments, while raising its adjusted earnings forecast for 2018 due to U.S. tax changes.

Continue Reading Below

The U.S. drugmaker raised its 2018 adjusted earnings per share forecast to $4.81 to $4.91 from $4.60-$4.70.

However, the company incurred $1.94 billion in charges in the fourth quarter related to the overhaul of the U.S. tax code.

The company also recognized asset impairment, restructuring and other charges of $1 billion in the quarter, primarily due to its cost-reduction efforts, including the U.S. voluntary early retirement program.

The charges pushed Lilly to a net loss of $1.66 billion, or $1.58 per share, in the three months ended Dec. 31, compared with a year-ago profit of $771.8 million, or 73 cents per share.

Excluding items, it earned $1.14 per share.

Continue Reading Below

Revenue rose nearly 7 percent to $6.16 billion.

Analysts on average had expected a profit of $1.07 per share and revenue of $5.94 billion, according to Thomson Reuters I/B/E/S. (Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)

Free America Network Articles

Leave a Reply

Next Post

The 9-year stock rally still has 'years left,' says one of Wall Street's most bullish strategists

The worst two-day decline for the Dow Jones industrial average since September 2016 was not the beginning of the end of the bull market, the chief investment strategist at Raymond James told CNBC on Wednesday. The U.S. futures were pointing to a rebound at the open on Wednesday after sharp […]